2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R02-R05
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MPN, CML, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human
PAPER

1078 Cost-effectiveness of first-line asciminib treatment in chronic myeloid leukemia

Rohan K Achar, MD, MSCR, Ding Quan Ng, PhD2, Henry Dumke, MD3, Razan Mansour, MD4, Luis E. Aguirre, MD, MPH5, Scott F. Huntington, MD, MPH6, Lourdes Mendez, MD, Ph D7, Alain Mina, MD8, Nikolai Podoltsev, MD, PhD9, Maximilian Stahl, MD10, Amer M. Zeidan, MD11, George Goshua, MD, SM12, Jan Philipp Bewersdorf, MD13
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States
7 Yale School of Medicine, New Haven, Connecticut, United States
8 Yale School of Medicine, New Haven, Connecticut, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Yale School of Medicine, New Haven, Connecticut, United States
12 Yale School of Medicine, New Haven, Connecticut, United States
13 Yale School of Medicine, New Haven, Connecticut, United States

*Co-first (RA, DQN), co-senior (GG, JPB) authors

Introduction: Asciminib (ASC), a novel first in class tyrosine kinase inhibitor (TKI) selectively inhibiting the myristoyl pocket, was recently approved in the United States for first-line (1L) treatment of chronic phase chronic myeloid leukemia (CML) with high rates of major molecular response (MMR) and deep molecular response (DMR) in the ASC4FIRST trial. Given the high cost of ASC and availability of lower-cost first-line TKIs including generic imatinib (IMAT) and dasatinib (DAS), we conducted a cost-effectiveness analysis of 1L ASC versus IMAT and DAS.

Methods: We built a microsimulation of ASC in 1L for treatment of CML against IMAT and DAS in 1L through the third-line (3L) setting as follows: i) 1L ASC to second-line (2L) DAS to 3L ponatinib (PON), ii) 1L IMAT to 2L DAS to 3L ASC, and iii) 1L DAS to 2L ASC to 3L PON. Transition probabilities and time-varying hazard distributions were informed from pivotal clinical trials—ASC4FIRST, DASISION, CA180-034, ASCEMBL, and PACE—with progression to accelerated/blast-phase CML and allogeneic stem cell transplant (HSCT) treatment through all 1-3L, as well as treatment-free remission (TFR) in 1-2L. Where trial data was insufficiently granular, real-world data supplemented trial-informed parameters. DMR rates were time-varying and drug-specific, while TFR attempt and failure rates were assumed constant across treatment arms with failure hazard distributions informed from the EUROSKI trial. Effectiveness was calculated in quality-adjusted life years (QALY) and parameterized from EQ-5D-3L CML-specific utilities while accounting for additional disutility from trial-reported treatment-related adverse events for each drug weighted by registry-sourced disutility estimates. Costs were derived from average wholesale drug pricing (AWP), Medicare-reimbursement rates, and observational analyses of advanced-phase CML and subsequent HSCT costs, with background mortality informed from national life tables. Microsimulation was executed with 10,000 patients with an ASC4FIRST median starting age of diagnosis at 52 years across all accepted US willingness-to-pay thresholds and reported at a base-case WTP of $120,000/QALY. The primary outcome was the net monetary benefit (NMB) of each strategy, where the decision rule is that the cost-effective strategy delivers most health for money spent (i.e., strategy with the highest positive NMB), and additionally reformulated into pairwise incremental cost-effectiveness ratios (ICER). The secondary outcome was a price threshold analysis for 1L ASC to become cost-effective. We concluded with sensitivity analyses to evaluate the effect of 1) model parameter variation and 2) second-order uncertainty on our conclusion across a two-dimensional (2D) evaluation of 1,000 sets of 5,000 patients each (i.e., 5 million patients).

Results: The 1L IMAT, 1L DAS, 1L ASC strategies accrued 13.77, 14.28, and 14.30 QALYs at costs of $1.1 million, $2.4 million, and $2.6 million, respectively. The net monetary benefits across the three strategies were $533,000 (95% CI: $499,000-$568,000), -$688,000 (95% CI: -$721,000 to -$650,000) and -$938,100 (95% CI: -$975,000 to -$901,000), respectively. Pairwise ICERs were $2.5 million/QALY for the comparison of 1L DAS vs 1L IMAT, $2.9 million/QALY for 1L ASC vs 1L IMAT, and $16.5 million/QALY for 1L ASC vs 1L DAS: all well above accepted US WTP thresholds. ASC drug cost led to the largest change in NMB, although no parameter variation in deterministic sensitivity analyses changed the conclusion that 1L IMAT was the cost-effective strategy. In probabilistic analysis, 1L IMAT was the cost-effective strategy across 100% of 2D iterations. In price threshold analysis, the ASC price for 1L ASC to become cost-effective was $53.73/pill, requiring a 94% reduction in current AWP.

Conclusion: Despite superior rates of MMR and DMR in 1L, ASC is not a cost-effective first-line treatment option for CML compared to IMAT or DAS even when considering TFR. These findings were robust across sensitivity analyses with 1L IMAT always the cost-effective strategy. This was driven by the high price of ASC relative to generic IMAT otherwise requiring a 94% price-reduction for 1L ASC to become the cost-effective strategy. These findings highlight the impact of generic drug pricing on the cost effectiveness of newer generation TKIs in the care of newly diagnosed patients with CML.
Rohan K Achar, MD, MSCR: No relevant conflicts of interest to declare.